MedTrace Logo

Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus.

NCT06150651 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2026-03-23

No results posted yet for this study

Summary

A Phase 1 clinical trial to evaluate the safety and efficacy of PiggyBac transposon-mediated Chimeric Antigen Receptor(CAR) T-cells targeting CD19 in refractory Systemic Lupus Erythematosus (SLE) patients who have not responded to standard immunosuppressive treatments.

Conditions

  • SLE (Systemic Lupus)

Interventions

OTHER

PiggyBac Transposon-Mediated CD19 CAR-T Therapy

PiggyBac Transposon-Mediated CD19 CAR-T Therapy (1-2 x 10\^6 cells/kg)

Sponsors & Collaborators

  • King Chulalongkorn Memorial Hospital

    collaborator OTHER

  • Health Systems Research Institute,Thailand

    collaborator OTHER_GOV

  • Chulalongkorn University

    lead OTHER

Principal Investigators

  • Wonngarm Kittanamongkolchai, MD · Chulalongkorn University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2026-03-01
Completion
2026-03-01

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06150651 on ClinicalTrials.gov